within Pharmacolibrary.Drugs.ATC.J;

model J05AX09
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.238,
    Cl             = 0.000595,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.194,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.017166666666666667,
    Tlag           = 10.319999999999999,            
    Vdp             = 0.165,
    k12             = 44.3,
    k21             = 44.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AX09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Maraviroc is an antiretroviral medication that acts as a CCR5 antagonist, used in combination therapy for the treatment of HIV-1 infection. It prevents viral entry into host cells by blocking the CCR5 co-receptor. Maraviroc is approved and currently in clinical use for HIV therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Abel, S, et al., &amp; Vourvahis, M (2009). Maraviroc: pharmacokinetics and drug interactions. <i>Antiviral therapy</i> 14(5) 607–618. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19704163/\">https://pubmed.ncbi.nlm.nih.gov/19704163</a></p></li><li><p>Pozniak, AL, et al., &amp; Muirhead, GJ (2008). A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. <i>British journal of clinical pharmacology</i> 65 Suppl 1(Suppl 1) 54–59. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2008.03136.x\">10.1111/j.1365-2125.2008.03136.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18333866/\">https://pubmed.ncbi.nlm.nih.gov/18333866</a></p></li><li><p>Abel, S, et al., &amp; Vourvahis, M (2009). Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment. <i>Antiviral therapy</i> 14(6) 831–837. DOI:<a href=\"https://doi.org/10.3851/IMP1297\">10.3851/IMP1297</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19812445/\">https://pubmed.ncbi.nlm.nih.gov/19812445</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AX09;
